Measles incidence and measles-containing vaccine coverage in Chereponi District, Ghana, 2019-2024: A retrospective analysis of routine surveillance and immunization data
Aug 2026· Global Epidemiology· Vol 12· 1 citation· 18 references
Medicine
TL;DR
Chereponi experienced substantial year-to-year variation in measles occurrence amid inconsistent two-dose MCV coverage and periods of high dropout, and Strengthening routine immunization, defaulter tracing, outreach, denominator validation, and case-based surveillance remains essential for measles elimination.
Abstract
Objectives To describe temporal patterns in measles occurrence and measles-containing vaccine (MCV) coverage in Chereponi District, Ghana, from 2019 to 2024. Methods A retrospective descriptive study analysed routine SORMAS and DHIMS2 data from 2019 to 2024. Annual suspected and laboratory-confirmed measles incidence, MCV1 and MCV2 coverage, and MCV1-MCV2 dropout were summarized descriptively. Results During 2019–2024, 167 suspected measles cases were reported through district surveillance, of which 31 (18.6%) were laboratory-confirmed. Children aged 0–4 years accounted for 66.9% of suspected cases with recorded age, while 5–9-year-olds accounted for 23.4%. Suspected notifications peaked in 2022, whereas laboratory-confirmed incidence was highest in 2023. MCV1 reached 95% only in 2020, while MCV2 remained below 90% in four of six years. MCV1-MCV2 dropout exceeded 10% in four years and declined to 8.6% in 2024. Conclusion Chereponi experienced substantial year-to-year variation in measles occurrence amid inconsistent two-dose MCV coverage and periods of high dropout. Strengthening routine immunization, defaulter tracing, outreach, denominator validation, and case-based surveillance remains essential for measles elimination.
In 2022, an estimated 1,36,000 measles deaths were reported worldwide, mostly in children under five. In 2022, thirty-seven countries reported extensive or disruptive measles outbreaks by the WHO, while only 22 countries reported similar outbreaks in 2021. According to NFHS-5, 87.9% of children between 12 and 23 months...
Gopi Kumbha, S. Choudhary, Mohankumar Raju et al.· BMC Infectious Diseases· 0 citations
Aims Documentable evidence of previous receipt of 2-dose of measles-containing vaccine (MCV) is often sufficient as proof of measles immunity in healthcare workers (HCWs). The usefulness of this policy was assessed by estimating the global prevalences of different MCV-receipt statuses in measles infected HCWs. Methods...
Sujata Saha, S. Saha· Journal of Infection Prevent...· 0 citations
Measles has resurged globally in the post-pandemic period as routine immunisation recovery remains below the two-dose threshold required to interrupt transmission. Bangladesh, previously nearing measles–rubella elimination, entered 2026 with widening coverage gaps, depleted vaccine stocks, and increasing numbers of mis...
Md. Kamrujjaman, F. Khondaker, A. A. Sarker et al.· Discover Public Health· 1 citation
Measles remains an important vaccine-preventable disease, and recent outbreaks have raised concerns about persistent immunity gaps following disruptions to routine immunization. This study describes the early 2026 measles outbreak in Bangladesh and contextualizes the epidemiological pattern within the broader South Asi...
The findings indicate suboptimal measles vaccination timeliness and highlight the need to strengthen postnatal care and maternal counseling to improve measles vaccination timeliness.
Boko Loka Safayi, A. Guye· Sage open pediatrics· 0 citations
OBJECTIVES
Somaliland has recurrent measles transmission, but outbreak-specific evidence on modifiable child, household, and health-service factors is limited. We examined factors associated with measles case status during the 2025-6 Burao outbreak.
METHODS
We conducted a community-based unmatched case-control study...
Dek Kahin Yosef, M. Farah, Fadumo Osman Ahmed· International Health· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.